
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
A. It is important to determine exactly what the patient meanswhen they present with the complaint of "breakouts." Most reputablecosmetic companies test their cosmetics and skincare products and can substantiate